MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday

MaxCyte (NASDAQ:MXCT - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $9.57 million for the quarter. MaxCyte has set its FY 2025 guidance at EPS.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). The firm had revenue of $10.39 million during the quarter, compared to analysts' expectations of $9.05 million. MaxCyte had a negative net margin of 110.92% and a negative return on equity of 19.90%. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Down 1.0%

MaxCyte stock traded down $0.02 during trading hours on Friday, hitting $2.04. The stock had a trading volume of 597,721 shares, compared to its average volume of 443,159. The stock has a market cap of $217.10 million, a price-to-earnings ratio of -5.10 and a beta of 1.23. MaxCyte has a one year low of $1.97 and a one year high of $5.20. The business's 50 day simple moving average is $2.21 and its 200-day simple moving average is $2.93.

Hedge Funds Weigh In On MaxCyte

An institutional investor recently raised its position in MaxCyte stock. AQR Capital Management LLC raised its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 227.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 95,501 shares of the company's stock after acquiring an additional 66,323 shares during the period. AQR Capital Management LLC owned approximately 0.09% of MaxCyte worth $261,000 as of its most recent filing with the SEC. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen upgraded MaxCyte from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Stephens initiated coverage on MaxCyte in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $6.00 price objective for the company.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.